Correspondence to editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".
作者信息
Chon Young Eun, Kim Dong Yun, Chon Hong Jae, Kim Do Young
机构信息
Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):1005-1008. doi: 10.3350/cmh.2024.0394. Epub 2024 May 30.
Abstract
摘要
相似文献
1
Correspondence to editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".
Clin Mol Hepatol. 2024 Oct;30(4):1005-1008. doi: 10.3350/cmh.2024.0394. Epub 2024 May 30.
2
Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".
Clin Mol Hepatol. 2024 Oct;30(4):682-688. doi: 10.3350/cmh.2024.0324. Epub 2024 May 7.
3
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
Clin Mol Hepatol. 2024 Jul;30(3):345-359. doi: 10.3350/cmh.2023.0553. Epub 2024 Mar 12.
4
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.
Cancers (Basel). 2024 Oct 17;16(20):3508. doi: 10.3390/cancers16203508.
5
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
World J Gastroenterol. 2021 May 21;27(19):2415-2433. doi: 10.3748/wjg.v27.i19.2415.
6
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Eur J Cancer. 2023 Aug;189:112933. doi: 10.1016/j.ejca.2023.05.021. Epub 2023 Jun 1.
7
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6.
8
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Oncology. 2025;103(6):456-468. doi: 10.1159/000541018. Epub 2024 Oct 11.
9
Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2024 Aug 10;16(16):2813. doi: 10.3390/cancers16162813.
10
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.
Cost Eff Resour Alloc. 2023 Mar 31;21(1):20. doi: 10.1186/s12962-023-00435-x.
本文引用的文献
1
Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".
Clin Mol Hepatol. 2024 Oct;30(4):682-688. doi: 10.3350/cmh.2024.0324. Epub 2024 May 7.
2
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
Clin Mol Hepatol. 2024 Jul;30(3):345-359. doi: 10.3350/cmh.2023.0553. Epub 2024 Mar 12.
3
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
Hepatology. 2024 Oct 1;80(4):807-815. doi: 10.1097/HEP.0000000000000776. Epub 2024 Feb 15.
4
Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
Anticancer Res. 2023 Oct;43(10):4673-4682. doi: 10.21873/anticanres.16663.
5
Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.
Biomedicines. 2022 Oct 5;10(10):2481. doi: 10.3390/biomedicines10102481.
6
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
J Cancer Res Clin Oncol. 2023 Jul;149(7):3065-3073. doi: 10.1007/s00432-022-04206-8. Epub 2022 Jul 21.
7
Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice.
Cancer Rep (Hoboken). 2023 Jan;6(1):e1679. doi: 10.1002/cnr2.1679. Epub 2022 Jul 13.
8
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
9
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Eur J Cancer. 2022 May;167:1-12. doi: 10.1016/j.ejca.2022.02.009. Epub 2022 Mar 29.
10
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.
Zotero 插件